Validation of an engineered cell model for in vitro and in vivo hif-1α evaluation by different imaging modalities

Molecular Imaging and Biology

Volumn 16, Issue 2, 2014, Pages 210-223

  Lo Dico, A ^a,b   Valtorta, S ^c,d,e   Martelli, C ^b,f   Belloli, S ^c,d,e   Gianelli, U ^a,g   Tosi, D ^f   Bosari, S ^a,b,g   Degrassi, A ^h   Russo, M ^h   Raccagni, I ^c,d,e   Lucignani, G ^b,f,i   Moresco, R M ^c,d,e   Ottobrini, L ^a,b,e  

^a UNIVERSITY OF MILAN   (Italy)

^b Dept Transfus Med and Blood Bank   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e CNR   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h NERVIANO MEDICAL SCIENCES   (Italy)

ⁱ SAN PAOLO HOSPITAL   (Italy)

Author keywords

Glioma; Hypoxia; MRI; Non invasive molecular imaging; Optical imaging; PET; Reporter gene; Tumor model

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3' FLUOROTHYMIDINE F 18; DEFEROXAMINE; FLUOROAZOMYCIN ARABINOFURANOSIDE F 18; FLUORODEOXYGLUCOSE F 18; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; LUCIFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BIOLUMINESCENCE IMAGING; CAMERA; CANCER CELL CULTURE; CELL ENGINEERING; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE IMAGING; GLIOMA CELL; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MITOSIS RATE; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REPORTER GENE; SPINDLE CELL; TUMOR GROWTH; TUMOR LOCALIZATION;

MURINAE; MUS;

ANIMALS; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL SHAPE; DEFEROXAMINE; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LUCIFERASES; MAGNETIC RESONANCE IMAGING; MICE; MODELS, BIOLOGICAL; MULTIMODAL IMAGING; OPTICAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896394612     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-013-0669-0     Document Type: Article

References (42)

1. Rankin EB, Rha J, Unger TL et al (2008) Hypoxia-inducible factor (HIF)-2 regulates vascular tumorigenesis in mice. Oncogene 27:5354-5358
2. Ivan M, Kaelin WG Jr (2001) The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 11:27-34, Review
3. Jaakkola P, Mole DR, Tian YM et al (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472
4. Cho S, Choi YJ, Kim JM et al (2001) Binding and regulation of HIF-1 by a subunit of the proteasome complex, PSMA7. FEBS Lett 498:62-66
5. Cockman ME, Masson N, Mole DR et al (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733-25741
6. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271:17771-17778
7. Lal A, Peters H, St Croix B (2001) Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93:1337-1343
8. Semenza G (2002) Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64:993-998
9. Ivan M, Kondo K, Yang H et al (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464-468
10. Candolfi CJF, Nichols WS et al (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85:133-148
11. Radaelli CR, Patton V et al (2009) Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol 24:879-891
12. Jacobs VL, Valdes PA, Hickey WF, De Leo JA (2011) Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumor model. ASN Neuro 3:e00063. doi: 10.1042/AN20110014
13. Louis DN, Seizinger BR (1994) Genetic basis of neurological tumors. Baillieres Clin Neurol 3:335-352, Review
14. Van Meir EG, Hadjipanayis CG, Norden AD et al (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60:166-193, Review
15. Koul TY, Shen R et al (2006) PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-kappaB signaling pathway in human glioma cells. Biochem Biophys Res Commun 2:463-471
16. Furnari FB, Fenton T, Bachoo RM (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683-2710, Review
17. Koul D, Shen R, Bergh S (2006) Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 3:637-644
18. Gheysens O, Chen IY, Rodriguez-Porcel M et al (2011) Non-invasive bioluminescence imaging of myoblast-mediated hypoxia-inducible factor-1 alpha gene transfer. Mol Imaging Biol 6:1124-1132
19. Szentirmai O, Baker CH, Lin N et al (2006) Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 2:365-372
20. Rapisarda A, Zalek J, Hollingshead M et al (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 19:6845-6848
21. Rapisarda A, Hollingshead M, Uranchimeg B et al (2009) Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 7:1867-1877
22. Rapisarda A, Uranchimeg B, Scudiero DA et al (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 15:4316-4324
23. MAES W, Deroose C, Reumers V (2009) In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma. J Neurooncol 91:127-139
24. 18F]FAZA: reaction parameters and automation. Appl Radiat Isot 62:897-901
25. 18F]FLT. Nucl Med Biol 29:263-273
26. Arsham AM, Plas DR, Thompson CB, Simon MC (2002) Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 277:15162-15170
27. Höckel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin Oncol 28:36-41, 2 Suppl 8
28. Yuan Y, Hilliard G, Ferguson T, Millhorn DE (2003) Cobalt inhibits the interaction between hypoxia-inducible factor-α and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-α. J Biol Chem 278:15911-15916
29. Demidenko ZN, Rapisarda A, Garayoa M et al (2005) Accumulation of hypoxia-inducible factor 1α is limited by transcription-dependent depletion. Oncogene 30:4829-4838
30. Stiehl DP, Wirthner R, Köditz J et al (2006) Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels: evidence for an autoregulatory oxygen-sensing system. J Biol Chem 33:23482-23491
31. Mottet D, Dumont V, Deccache Y et al (2003) Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 33:31277-31285
32. Görlach A (2009) Regulation of HIF-1alpha at the transcriptional level. Curr Pharm Des 33:3844-52, Review
33. Zundel W, Schindler C, Haas-Kogan D et al (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14(4):391-396
34. Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1 expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 6:1541-1545
35. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240-4245
36. Rong Y, Hu F, Huang R et al (2006) Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res 66:7067-7074
37. 18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuroncology 1:41-56
38. 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46:945-952
39. 18F]FAZA-first small animal PET results. J Pharm Pharm Sci 10:203-211
40. 64Cu-diacetyl- bis(N4-methylthiosemicarbazone) in preclinical models of cancer. J Nucl Med 54:1-7. doi: 10.2967/JNUMED.112.111120
41. Randy LJ (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92:317-335, Review
42. Stell A, Biserni A, Della Torre A (2007) Generation of novel animal model systems to study cancer progression and therapy. Int J Biochem Cell Biol 39(7-8):1288-1296, Review